Figure 1.
Effect of Bortezomib on AngII-induced Hypertension.
This figure shows mean arterial pressure in conscious rats 13 days after vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort) or combined AngII/Bortezomib treatment (AngII/Bort). N = 5 in each group. Overall ANOVA p = 0.0005. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in the figure.
Table 1.
Body Weights
Figure 2.
Chymotrypsin-like proteasome activity in rat tibialis anterior skeletal muscle.
Rats were sacrificed and tibialis anterior skeletal muscle samples were collected 14 days after vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort) or combined AngII/Bortezomib treatment (AngII/Bort). N = 5. Overall ANOVA p = 0.015. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in the figure
Figure 3.
Effect of Bortezomib on AngII-induced aortic remodeling.
Figure 3A shows photos of Masson's trichrome staining of aortas (5× magnification). Figure 3B shows the medial cross sectional area. Figure 3C shows the aorta inner lumen area. Figure 3D shows the aorta medial cross sectional area to inner lumen area ratio. Vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort) or combined AngII and bortezomib treatment (AngII/Bort). N = 5. Overall ANOVA Fig. 3B p = 0.01, Fig. 3C p = 0.66, Fig. 3D p = 0.0003. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in each figure
Figure 4.
Effect of Bortezomib on Collagen Deposition in AngII hypertension.
Figure 4A shows photos of Masson's trichrome staining of aortas (100X). Figure 4B represents the density of collagen staining in aortic smooth muscle wall. Vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort) or combined AngII and bortezomib treatment (AngII/Bort). N = 4. Overall ANOVA p = 0.003. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in the figure.
Figure 5.
Effect of Bortezomib on AngII-induced Hypertensive Changes in TIMP Expression.
For figure 5A, the upper panel is the western blot result of TIMP1 in aorta and the lower panel is a summary of densitometric values. For figure 5B, the upper panel is the western blot result of TIMP2 in aorta with the lower panel as the densitometry. Vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort), AngII and bortezomib treatment (AngII/Bort). N = 3. Overall ANOVA Fig. 5A p = 0.02, Fig. 5B p = 0.003. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in each figure.
Figure 6.
Effect of Bortezomib on AngII-induced Hypertensive Changes in MMP2 Activity.
The image of MMP2 zymography gel is shown in the upper panel. The lower panel shows summary data for the brightness of the bands representing the activated forms of MMP2. Vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort), AngII and bortezomib treatment (AngII/Bort). N = 3. Overall ANOVA p = 0.02. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in the figure.
Figure 7.
Effect of bortezomib on an index of cellular proliferation in aorta.
Images of Ki67 staining in the aorta from each group are illustrated on the left. The right side shows summary data for each group. Vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort), AngII and bortezomib treatment (AngII/Bort). N = 3. Overall ANOVA p = 0.005. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in the figure.
Figure 8.
Effect of bortezomib on aortic ROS and VCAM staining.
The top panel A shows images of dihydroethidium (DHE) staining (red) in aorta on the left and summary data for each group on the right. The lower panel side B show individual images for VCAM-1 staining (brown reaction product) in aorta on the left and summary data for VCAM-1 staining on the right. Vehicle saline and vehicle cyclodextrin treatment (Veh), AngII continuous infusion (AngII), bortezomib treatment (Bort), AngII and bortezomib treatment (AngII/Bort). N = 3. Overall ANOVA Fig. 8A p = 0.02, Fig. 8B p<0.0001. Post hoc analysis (Newman Keuls) for Veh versus Ang II and AngII versus AngII+Bort comparisons shown in each figure.